Drawing on advances in genomics, proteomics and next-generation sequencing, SMi’s 6th annual Biomarkers Summit brings you the latest developments in this exciting field. From compound screening and toxicity testing to companion diagnostic assays, stay competitive with fresh insights from companies at the cutting edge of biopharmaceutical development. You cannot afford to miss this event Reasons to attend this exciting event include: Accelerate companion diagnostics development for therapeutic indicationsValidate and deliver biomarkers for patient selection during clinical trialsImplement sub-grouping in patient segmentation studiesUtilise revised FDA regulatory guidelines to aid product developmentOptimise reimbursement strategies for diagnosticsMaximise biomarker identification using epigenetic and metabolomic insights Key speakers include: Adam Platt, Diagnostic Development Director, AstraZenecaAndrew Warren, Director, PK/PD/Immunogenicity Bioanalysis, Novartis PharmaChristopher Foley, Clinical Imaging Manager, GlaxoSmithKlineGraham Bell, Lead Technologist, Stratified Medicine, Technology Strategy BoardMirella Lazarov, Senior Director Biology, Head of Biomarkers, Gilead SciencesNicholas Buss, Toxicology Project Leader, MedImmuneNick Crabb, Associate Director - Diagnostics Assessment Programme, National Institute for Health and Clinical Excellence Contact Farhaan Rahman on tel +44 0207 827 6186